Formation Bio
Formation Bio is a tech-driven, AI-native pharmaceutical company revolutionizing drug development. By leveraging a proprietary technology platform, they expedite the development of treatments, aiming to meet critical unmet patient needs efficiently without compromising quality or safety. They acquire clinical-stage drugs from various sources and enhance their development process to achieve faster inflection points than industry norms. Their multidisciplinary team combines extensive expertise in drug selection, development, and technology, having collectively worked on over 45 approved drugs, ensuring a robust and innovative approach to bringing new treatments to patients.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
Company valuation calculator
To calculate, specify one of the parameters
News related to Formation Bio2
Formation Bio collaborates with Sanofi and OpenAI to Introduce ...
PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug....
https://www.prnewswire.com/news-releases/formation-bio-collaborates-with-sanofi-and-openai-to-introduce-muse-a-first-of-its-kind-ai-tool-to-accelerate-patient-recruitment-in-drug-development-302301958.htmlFormation Bio secures $372MM Series D funding to grow drug pipeline and continue expanding AI-driven drug development platform
The company plans to allocate the new capital towards two primary objectives: acquiring and ...
https://www.prnewswire.com/news-releases/formation-bio-secures-372mm-series-d-funding-to-grow-drug-pipeline-and-continue-expanding-ai-driven-drug-development-platform-302182347.html